BS
VRTX icon

Boenning & Scattergood’s Vertex Pharmaceuticals VRTX Stock Holding History

Boenning & Scattergood’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$634K Buy
2,428
+300
+14% +$91.4K 0.1% 221
2022
Q3 		$616K Hold
2,128
– – 0.13% 188
2022
Q2 		$600K Sell
2,128
-300
-12% -$80.3K 0.11% 197
2022
Q1 		$634K Buy
2,428
+900
+59% +$214K 0.1% 221
2021
Q4 		$336K Buy
1,528
+50
+3% +$9.72K 0.05% 306
2021
Q3 		$268K Sell
1,478
-50
-3% -$9.76K 0.05% 320
2021
Q2 		$308K Sell
1,528
-1,089
-42% -$228K 0.05% 301
2021
Q1 		$562K Buy
2,617
+34
+1% +$7.47K 0.11% 214
2020
Q4 		$610K Buy
2,583
+1,136
+79% +$261K 0.13% 176
2020
Q3 		$394K Buy
1,447
+11
+0.8% +$3.04K 0.09% 213
2020
Q2 		$417K Buy
+1,436
New +$389K 0.11% 195

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Boenning & Scattergood's VRTX Position: Q4 2022 in Review

Boenning & Scattergood increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q4 2022, buying an estimated $91.4K and bringing the position to 2,428 shares worth $634K. The position accounts for 0.1% of the portfolio, ranked #221.

Boenning & Scattergood first reported a position in VRTX in Q2 2020 and has held it in 11 quarters since. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Boenning & Scattergood held 2,428 shares of Vertex Pharmaceuticals worth $634K as of Q4 2022.
  • Boenning & Scattergood bought 300 Vertex Pharmaceuticals shares in Q4 2022, an estimated $91.4K.
  • Vertex Pharmaceuticals made up 0.1% of Boenning & Scattergood's portfolio in Q4 2022, its #221 holding.
  • Boenning & Scattergood first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
  • 1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Boenning & Scattergood's 13F filing for Q4 2022, filed 26 Jan 2023.